The CEO+CFO simultaneous open-market sales without a 10b5-1 plan or disclosed catalyst is a cautionary signal for a high-valuation biotech. Monitor for upcoming pipeline data readouts or clinical trial updates that may have prompted insider selling. The 95% analyst bullish consensus creates downside risk if insiders are proven correct.
Price Chart
Executive Summary
Relay Therapeutics' CEO and CFO sold a combined $1.33M in open-market sales over a 4-day window, representing ~0.03% of the $4.5B market cap. While the dollar amount is trivial relative to company size, the cluster involves both the CEO and CFO selling simultaneously, which is notable for a biotech with a $4.5B market cap and 95% analyst bullishness. The sales are not part of a 10b5-1 plan pattern and occur without any disclosed negative catalyst, suggesting potential insider caution ahead of upcoming pipeline data or earnings.
Key Financial Metrics
Key Facts
- CEO Sanjiv Patel sold 48,199 shares for $979,886 on 2026-08-17
- CFO Thomas Catinazzo sold 17,717 shares for $349,734 on 2026-08-14
- Total insider sales of $1.33M represent ~0.03% of $4.5B market cap
- Both sales are open-market (code S), not 10b5-1 plan or tax withholding
- No recent positive catalyst or earnings release to explain selling
- 95% of analysts rate the stock Buy/Strong Buy
Financial Impact
Insider sales of $1.33M, trivial relative to $4.5B market cap (0.03%)
Risk Factors
- Insider sales may signal management's lack of confidence in near-term pipeline catalysts
- High analyst bullishness (95% Buy/Strong Buy) creates asymmetric downside if sentiment shifts
- No disclosed negative catalyst — selling could be diversification but timing is suspicious
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-RLAY-1787121416661 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 9, 2026 23d ago | Insider Cluster | $18.66 $18.84 | ▲ +0.96% | ▲ +1.62% | $18.96 (+1.61%) |
Aug 28, 2026 5w ago | Insider Cluster | $18.77 $19.04 | ▼ −1.44% | ▼ −1.33% | $18.96 (−1.01%) |
Aug 18, 2026 6w ago | Insider Cluster | $20.61 $20.57 | ▲ +0.19% | ▼ −0.01% | $18.96 (+8.01%) |
Jul 8, 2026 12w ago | Insider Cluster | $19.63 $19.08 | ▼ −2.80% | ▼ −3.66% | $18.96 (−3.41%) |
Jun 22, 2026 14w ago | 144 | $17.44 $19.74 | ▲ +13.19% | ▲ +12.18% | $18.96 (+8.72%) |
Jun 12, 2026 16w ago | Institutional Cluster | $14.81 $15.88 | ▲ +7.22% | ▲ +6.55% | $18.96 (+28.02%) |
May 21, 2026 19w ago | 8-K | $13.53 $14.26 | ▼ −5.40% | ▼ −3.74% | $18.96 (−40.13%) |
May 21, 2026 19w ago | Press Release | $13.66 $14.05 | ▼ −2.86% | ▼ −1.01% | $18.96 (−38.80%) |
May 19, 2026 19w ago | 424B5 | $13.02 $13.90 | ▼ −6.76% | ▼ −4.96% | $18.96 (−45.62%) |
May 19, 2026 19w ago | Press Release | $13.02 $14.43 | ▼ −10.83% | ▼ −9.59% | $18.96 (−45.62%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access